New Gastrointestinal Rebleeding Prevention...Additional hemostatic powder treatment reduces rebleeding to 25%
Oct 15, 2025
|
A research team led by professors Kim Kyung-oh, Kwon Kwang-an, and Jung Joon-won of the Department of Gachon University Gil Medical Center has proven a new treatment method that can effectively reduce rebleeding of patients with hemorrhagic stomach and duodenal ulcers and published it in a global journal.
The research team confirmed that the rebleeding rate was significantly reduced when the hemostatic powder 'Nexpowder' developed by Next Biomedical was additionally applied to the existing endoscopic treatment. Under the title of 'Prevention of Reproductive After Primary Haemostasis using haemostatic powder in non-variable upper gastrostatic bleeding: a multicentre randomized controlled trial', the world's most prestigious international journal of digestive organs, was published with a citation index of 23.5 points.
Upper gastrointestinal rebleeding is a very common disease and is considered one of the leading causes of emergency room visits and hospitalizations worldwide. In the United States, more than 200,000 cases occur every year, and it is reported that about 14 to 25% of patients who received endoscopic treatment experience rebleeding within 72 hours.
Rebleeding leads to ▲ increased mortality ▲ increased hospitalization period ▲ burden of additional procedures, which is a great risk factor for both patients and medical staff.
However, no special precautions have been taken until now. Mainly endoscopic hemostasis and administration of proton pump inhibitors (PPIs) are the only proven standard methods to prevent rebleeding, but there was no definite effect.
From November 2018 to November 2021, the research team conducted clinical trials on patients who visited Gachon University Gil Hospital, Inha University Hospital, and Soonchunhyang University Hospital due to upper gastrointestinal bleeding. Of a total of 348 subjects, 341 who succeeded in primary hemostasis with endoscopy were the final subjects of analysis. The average age of the subjects was 64.8 years, about 72% of all patients were male, and most of the subjects were peptic ulcer patients.
The research team randomly divided the subjects into A group (173 people) and B group (168 people) and compared the effects. Group A added Nexpowder after endoscopic treatment, and group B applied only standard treatment without additional treatment.
The clinical trial showed that the rebleeding rate within 72 hours in group A with Nexpowder was 2.9%, which was about a quarter lower than that in group B with 11.3%.
Even when only patients with peptic ulcers were analyzed separately, group A showed a rebleeding rate of 3.0%, while group B showed 12.0%, confirming the effect of preventing rebleeding.
Similar results were found in long-term follow-up. The cumulative rebleeding rate on the 30th day after the procedure was 7.0% in group A, while 18.8% in group B, which differed by about 2.7 times. Long-term follow-up of peptic ulcer patients also showed the same trend as Group A 7.2% versus Group B 19.3%. All figures showed statistically significant differences.
The safety evaluation also yielded positive results. Not a single adverse event directly related to Nexpowder use has been reported. There were no major complications such as embolization, intestinal obstruction, allergic reaction, or perforation.
Professor Kim Kyung-oh of the Department of Gachon University Gil Hospital said "The first clinical trial to prove that NexFounder can dramatically reduce the rebleeding rate when added to the existing endoscopic treatment"This is expected to increase the survival rate of patients and reduce readmission and medical costs"
Professor Yunjae Kim, who conducted the study together, emphasized that "Nex Powder has the property of stabilizing the bleeding area by forming a strong hydrogel protective film on the ulcer lesion" and "meaningful achievements that have shown that the risk of rebleeding can be further reduced 20 years after the introduction of proton pump inhibitors."
Meanwhile, this study was conducted as a multi-center randomized controlled clinical trial with the support of the Ministry of Health and Welfare's Health and Medical Technology Development Project. In addition, Shin Jong-beom, Cha Bo-ram, a professor of gastroenterology at Inha University Hospital, Hong Soo-jin, a professor of gastroenterology at Soonchunhyang University Hospital, and Park Dong-kyun and Kim Yoon-jae, a specialist in Jang Good Medicine, participated in the study.
◇ Gastric and duodenal bleeding, one in four rebleeds within 72 hours
Gastric and duodenal ulcers are common digestive diseases in Korea and around the world, and bleeding can lead to life-threatening emergencies. In particular, it has been reported that patients with bleeding have rebleeding within 72 hours, even if they receive hemostatic treatment through endoscopy.
Rebleeding is a major cause of rapid deterioration of the patient's condition. Not only does it increase the risk of death of patients and increase the length of hospitalization, but it also requires additional treatment such as endoscopic reoperation, reoperation, and vascular embolization, greatly increasing the burden on the patient's medical staff.
For this reason, preventing rebleeding of patients with gastric and duodenal ulcers is a very important issue in improving the survival rate and quality of life of patients.
Previously, the administration of proton pump inhibitors (PPIs) after endoscopic hemostasis was established as the standard treatment, but this method alone was difficult to prevent rebleeding sufficiently.
Professor Kim Kyung-oh said "The need for new treatments to reduce the risk of rebleeding in ulcer patients has been continuously raised" and "This study is significant in that it proves that rebleeding can be safely and effectively prevented"
|
This article was translated by Naver AI translator.
